country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P5314

Copy Link Print Information

OK2

Kundenbewertung

Based on 1 Customer Validation

OK2, a specific inhibitor of the CCN2/EGFR interaction, efficiently blocks CCN2/EGFR interaction through binding to the CT domain of CCN2. OK2 can be used for kidney fibrosis and chronic kidney disease research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.13%
CAS. Nr.: 2983020-14-8
Formel: C₄₂H₆₂N₁₄O₉
Molecular Weight:907.03

Speicherung:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

OK2 Chemical Structure

CAS. Nr.: 2983020-14-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

p-STAT3

Alle EGFR Isoform-spezifische Produkte anzeigen :

Alle STAT Isoform-spezifische Produkte anzeigen :

In Vitro

OK2 (0-100 μM; 24 hours) inhibits EGFR activation, STAT3 phosphorylation, and ECM protein synthesis in HK-2 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

HK-2 cells
Concentration:

0, 4, 20, 100 μM
Incubation Time:

24 hours
Result:

Blocked thevastmajority ofEGFR activation in therenalfibrosis cell model, thereby preventing EGFRmediated STAT3 phosphorylation andECMprotein synthesis.
Inhibited EGFR-mediated ECM protein synthesis in a dose dependent manner and exhibited a significant blocking effect beginning at 20 μM.

In Vivo

OK2 (50 μg/kg, i.p., for 14 days) blocks CCN2-induced EGFR/STAT3 activation and impede kidney fibrosis in the unilateral ureteric obstruction (UUO) mice model^[1].
OK2 (1 mg/kg, s.c.) shows a T_1/2 of 0.9 h and C_max of 1057.8 ng/mL in male Sprague Dawley rats^[1].
Pharmacokinetic parameters for OK2 in male Sprague Dawley rats ^[1]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Unilateral ureteric obstruction (UUO)-induced renal fibrosis ^[1]
Dosage:

50 μg/kg
Administration:

Intraperitoneal injection (i.p.) for 14 days
Result:

Alleviated renal tubular injury and inflammatory infiltration, as well as suppressed collagen formation in the left kidney.
Inhibited the phosphorylation of EGFR and STAT3 and reduced the vast majority of fibronectin and type I collagen synthesis.

Animal Model:

Male Sprague Dawley rats(Pharmacokinetic assay)^[1]
Dosage:

1 mg/kg
Administration:

Subcutaneous injection (s.c.)
Result:

Showed a T_1/2 of 0.9 h and C_max of 1057.8 ng/mL in male Sprague Dawley rats^[1].

Chemical Information

CAS. Nr. 2983020-14-8
Appearance Solid
Molecular Weight 907.03
Formel C₄₂H₆₂N₁₄O₉
Color White to off-white
Sequence

cyclo-(Thr-Lys-His-Arg-Pro-Trp-Thr)
Sequence Shortening

cyclo-(TKHRPWT)
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Sealed storage, away from moisture

Route	Dose (mg/kg)	C_max (ng/mL)	T_max (h)	T_1/2 (h)	AUC_0-t (h•ng/mL)
s.c.	1	1057.8	1.0	0.9	3032.0

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (110.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1025 mL

5.5125 mL

11.0250 mL

5 mM

0.2205 mL

1.1025 mL

2.2050 mL

10 mM

0.1102 mL

0.5512 mL

1.1025 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Dong J, et.al. Discovery and Design of Novel Cyclic Peptides as Specific Inhibitors Targeting CCN2 and Disrupting CCN2/EGFR Interaction for Kidney Fibrosis Treatment. J Med Chem. 2023 Jun 22;66(12):8251-8266. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1025 mL	5.5125 mL	11.0250 mL	27.5625 mL
	5 mM	0.2205 mL	1.1025 mL	2.2050 mL	5.5125 mL
	10 mM	0.1102 mL	0.5512 mL	1.1025 mL	2.7562 mL
	15 mM	0.0735 mL	0.3675 mL	0.7350 mL	1.8375 mL
	20 mM	0.0551 mL	0.2756 mL	0.5512 mL	1.3781 mL
	25 mM	0.0441 mL	0.2205 mL	0.4410 mL	1.1025 mL
	30 mM	0.0367 mL	0.1837 mL	0.3675 mL	0.9187 mL
	40 mM	0.0276 mL	0.1378 mL	0.2756 mL	0.6891 mL
	50 mM	0.0220 mL	0.1102 mL	0.2205 mL	0.5512 mL
	60 mM	0.0184 mL	0.0919 mL	0.1837 mL	0.4594 mL
	80 mM	0.0138 mL	0.0689 mL	0.1378 mL	0.3445 mL
	100 mM	0.0110 mL	0.0551 mL	0.1102 mL	0.2756 mL

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

OK2

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Macrocyclic Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Alle EGFR Isoform-spezifische Produkte anzeigen

Alle STAT Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

OK2 Related Classifications

HY-P5314 Related Classifications